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Background: The PANORAMA studywasdesigned to collect concurrent data on subjects fromdifferentworldwide
regions implanted with CRM devices.
Methods: In this prospective, multi-center study, we analyzed baseline data on 8586 subjects implanted with
CRM devices with no additional selection criteria (66% pacemaker (IPG), 16% implantable cardiac deﬁbrillators
(ICD), 17% cardiac resynchronization therapy (CRT) and b1% Internal Loop Recorder) from 156 hospitals across
6 geographical regions between 2005 and 2011.
Results: Regardless of the device implanted, subjects from theMiddle East and India often hadmore diabetes than
other regions. Eastern and Western Europe had higher rates of atrial ﬁbrillation reported, and men were more
likely to smoke than women (46% vs 11%, p b 0.001). Within the CRT cohort there was signiﬁcant variation in
the proportion of males receiving a device, ranging from 55% in India to 83% in Eastern Europe.
Conclusions: We provide comprehensive descriptive data on patients receiving CRM devices from a range of
geographies that are not typically reported in literature.We found signiﬁcant variations in clinical characteristics
and implant practices. Long term follow-up datawill help evaluate if these variations require adjustments to out-
come expectations.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Device therapies for treating cardiac rhythm disorders include pace-
makers (IPG) and implantable cardiac deﬁbrillators (ICD), both withtor; IPG, implantable pulse gen-
diac rhythm management; AV,
thmDiseaseManagement, 8200
A. Tel.: +1 763 526 2772.
lbrook).
ability and freedom frombias of
and Ltd. This is an open access articleand without cardiac resynchronization therapy (CRT). Randomized tri-
als have established the effectiveness of device therapies for cardiac
rhythm and disease management [1–5]. These trials have played an
important role in establishing guidelines for the application of these
therapies.
Translating evidence from randomized trials into global clinical
practice guidelines involves extrapolating results from a study cohort
to the population of interest in the guideline. However it is not a priori
certain that study results from a speciﬁc patient population in a speciﬁc
region can be extrapolated to a less well-deﬁned patient population or
to other geographies. Regional variations in disease incidence [6–8],
patient demographics and comorbidities [9], genetics [10], health-
care systems and reimbursement conditions [11], cultural attitudes tounder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
91F. Al Kandari et al. / IJC Heart & Vessels 4 (2014) 90–96disease and implant practices exist which affect the choice of therapy
and may inﬂuence the expected therapy outcomes [12]. Risk factors
can be considered and treated differently across geographies [13] and
approaches to diagnostic testing can also differ. Understanding the
patients, the practice patterns and the healthcare settings of a geogra-
phy are important for setting expectations and interpreting patient
outcomes.
While randomized trials are indispensable in understanding the
beneﬁt of therapies in strictly controlled settings, observational studies
are designed to assess the relevance and credibility of clinical trial out-
comes in real-life settings [14]. Our current understanding of the real
world application of cardiac rhythm management (CRM) therapies
comes largely from registries conducted in North America and
Europe [15,16]. To date there is little evidence available to shed light
on regional differences in practice patterns, particularly to understand
demographics, comorbidities and treatment patterns in emerging
geographies.
This is the ﬁrst report of the world wide PANORAMA study, a long
term, multi-center, prospective, non-randomized observational study.
The primary purpose of the study was to construct a computerized
database of national proﬁles and epidemiological data on patients
wearing Medtronic implantable pacemakers, cardioverter deﬁbrilla-
tors (both with and without cardiac resynchronization therapy), and
implantable loop recorders. The study was conducted in 34 countries
across 6 geographical regions. Minimal selection criteria ensured
that the study population included elderly patients, patients with
comorbidities and patients presenting for a replacement device in
an effort to ensure that participants were representative of patients
receiving therapy for cardiac rhythm disorders. The objective of
this analysis is to describe the patients and implant procedures and
to provide information on clinical characteristics in regions previ-
ously underrepresented.
2. Methods
2.1. Study population
Consenting patients included those who were implanted (either de
novo device or replacement) with a Medtronic market-released CRM
device (IPG or ICD with or without CRT capability); no other selection
criteria were applied. The protocol speciﬁed that enrollment should
take placewithin 30 days of the planned/performed implant procedure.
PANORAMA (ClinicalTrials.gov Identiﬁer: NCT00382525) was
designed and conducted in compliance with the local ethical consider-
ations and according to the principles outlined in the ‘World Medical
Association Declaration of Helsinki’ (October 2000) and the laws and
regulations in the countries in which the study was conducted. The
study was submitted to locally appointed ethics committees and in-
formed consent was obtained from the subjects (or their guardians).
Patientswere enrolled from6geographies: Latin America (Argentina,
Bahamas, Brazil, Colombia, Dominican Republic, Ecuador, Mexico,
Puerto Rico, Uruguay, Venezuela, and Virgin Islands), Western Europe
(Austria, Belgium, Denmark, Spain, Germany, Greece, Luxemburg,
Netherlands, and United Kingdom), Eastern Europe (Belarus, Czech
Republic, Latvia, Lithuania, Poland, Romania, Russian Federation,
Serbia, Slovakia, and Turkey), Middle East (Kuwait and Saudi Arabia),
South Africa and India.
2.2. Study design
Patients were assessed at study entry and during follow-up visits for
at least 1 year after implant. Patients were followed according to the
standard follow-up visit scheme of the participating centers, and did
not require any procedures beyond regular practice. All treatment deci-
sions were at the discretion of the treating physician. PANORAMA was
designed to enroll 10,000 patients.2.3. Data collection and measures
Clinical data were collected by the investigators using an electronic
case report form designed speciﬁcally for the study, and stored in a
centralized database. The data collected at baseline included demo-
graphics and clinical characteristics, medical history, and cardiovascular
pharmacological therapy. At implant, data were collected on the im-
plantation procedure and techniques, adverse experiences and device
programming.
The IPG cohort includes patients implanted with a single or dual
chamber pacemaker. Indications were deﬁned as: AV block (any form
of atrioventricular conduction disorder), sinus node disease (any form
of atrial based bradyarrhythmia) or other (neither of the previous
two). The ICD cohort includes patients implanted with a single or dual
chamber ICD. Indicationswere deﬁned as: secondary prevention (survi-
vor of prior sustained ventricular tachyarrhythmia) or primary preven-
tion (risk factors for sudden cardiac arrest without prior episode). The
CRT cohort includes patients implanted with a CRT-D or a CRT-P.
2.4. Statistics
Data are reported as mean + standard deviation (SD), median (in-
terquartile range (IQR)) or as n (percentage). For continuous variables,
comparisons across the regional groups were made using analysis of
variance (ANOVA) with pairwise comparisons performed using Tukey's
studentized range test. For categorical variables a chi-square test was
used. All statistical analyses were performed using SAS software version
9.3 (SAS Institute). P values less than 0.05 were considered statistically
signiﬁcant. Stratiﬁcation of the analysis was speciﬁed a priori by region,
pathology, indication, and device type.
3. Results
A total of 10,064 subjects were enrolled in the PANORAMA study
between 2005 and 2011. From the total study population 1478 patients
were excluded from the database due to the lack of evidence of a signed
Patient Informed Consent or Patient Data Release Form (1428), or
because the samepatientwas, bymistake, created twice in the electron-
ic database (50). This analysis includes data of the remaining 8586 sub-
jects, all implanted with a CRM device, and enrolled by 156 centers
across 34 countries. Two thirds of the study population was implanted
with an IPG, 16% with ICD, 17% with CRT, and 1% were implanted with
an implantable loop recorder or missing information about the device
type. One third of the subjects were enrolled from Eastern Europe
(EE), 17% from Western Europe (WE), 17% from South Africa (SA),
17% from the Middle East (ME), 13% from Latin America (LA) and 7%
from India (IN) (Table 1).
Regardless of the type of device implanted, several cardiovascu-
lar risk factor patterns were noted to be similar. In particular, sub-
jects from the Middle East had substantially more diabetes present
than other regions (47% vs 20% EE, 19% LA, 15% SA, 25% WE, 33% IN,
p b 0.001 for ME vs all); subjects from India were signiﬁcantly lighter
in weight (66 ± 13 kg vs 81 ± 16 EE, 71 ± 15 LA, 82 ± 20 SA, 79 ±
16 WE, 76 ± 19 ME, p b 0.001 for IN vs all) and in all regions men
were more likely to smoke than females (46% vs 11%, p b 0.001).
There were also distinct differences in the amount of atrial ﬁbrilla-
tion reported across the regions with Eastern and Western Europe
reporting more atrial ﬁbrillation than other regions (42% EE and
36% WE vs 15% LA, 15% ME, 26% SA, 9% IN, p b 0.001 for EE vs all and
p b 0.05 for WE vs all).
The use of general anesthesia for all types of device implants was
higher in Latin America than in other regions (26% vs 2% EE, 1% IN, 2%
ME, 12% SA, 14% WE, p b 0.001 for LA vs all).
In the IPG cohort 46% were female and 41% were aged over or equal
to 75 years of age. Table 2 reports the baseline and initial treatment
characteristics of patients who received IPG therapy stratiﬁed by region.
Table 1
Overall baseline demographics and device characteristics by region.
Characteristics Total Eastern Europe India Latin America Middle East South Africa Western Europe
n = 8586 n = 2496 n = 571 n = 1127 n = 1463 n = 1432 n = 1497
Number of countries 34 10 1 11 2 1 9
Number of sites 156 34 9 34 5 13 61
Device (%)
IPG 5592 (65) 1769 (71) 368 (64) 840 (75) 782 (53) 827 (58) 1006 (67)
ICD 1407 (16) 322 (13) 94 (16) 129 (11) 400 (27) 61 (4) 401 (27)
CRT 1455 (17) 400 (16) 108 (19) 116 (10) 276 (19) 469 (33) 86 (6)
Othera 132 (2) 5 (b1) 1 (b1) 42 (4) 5 (b1) 75 (5) 46 (1)
IPG = pacemaker; ICD = implantable cardiac deﬁbrillator; CRT = cardiac resynchronization therapy; IQR = interquartile range.
a Other includes implantable loop recorder (n = 76), missing (n = 56).
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ranging from 65 years in the Middle East and India to 76 years inWest-
ern Europe (p b 0.001), which remained even after adjusting for
replacement device. AV block as a primary indication for implant was
more common in India (77%), Latin America (62%) and the Middle
East (72%) and least frequent in South Africa (26%) (p b 0.001). 22% of
the IPG cohort was implanted with a single chamber device with the
highest numbers in Latin America (25%), the Middle East (30%) and
South Africa (31%) (p b 0.001). In 62% of the patients implanted with
a single chamber device, persistent or permanent AF had not been
reported.Table 2
Baseline demographics, device and implant characteristics for the IPG cohort by region.
Characteristics Total Eastern Europe India
n = 5592 n (%) n = 1769 n (%) n = 3
Median age, years (IQR) 72 (63,79) 73 (66,79) 65 (
Male 3030 (54) 884 (50) 236 (
Indication
Sinus node dysfunction 2421 (43) 920 (52) 75 (
AV block 2733 (49) 686 (39) 283 (
Othera 431 (8) 161 (9) 10 (
Body mass index (kg/m2)
Mean (SD) 27 (5.3) 28 (4.7) 25 (
Overweight/obeseb 2914 (52%) 1033 (58%) 170 (
Previous or current smoker 1558 (28) 478 (27) 55 (
Hypertension 3418 (61) 1321 (75) 164 (
Diabetes 1258 (23) 379 (21) 118 (
Coronary artery disease 1256 (23) 441 (25) 133 (
Prior myocardial infarction 477 (9) 237 (13) 17 (
Coronary artery bypass grafting 340 (6) 93 (5) 30 (
Mean ejection fraction, % (SD) 57 (11.9) 55 (10.4) 54 (
NYHA
I 742 (13) 369 (21) 26 (
II 1273 (23) 768 (43) 109 (
III 340 (6) 168 (10) 52 (
IV 44 (1) 11 (1) 3 (
No heart failure 3175 (57) 451 (26) 178 (
Atrial ﬁbrillation
Paroxysmal 1093 (20) 586 (33) 33 (
Persistent/permanent 847 (11) 226 (13) 5 (
CHADS2 score 2 or more 2960 (53) 1192 (67) 170 (
Single chamber device 1236 (22) 363 (21) 57 (
Specialization of implanting physicianc
Electrophysiologist 2122 (38) 436 (25) 363 (
Cardiologist 2516 (45) 765 (43) 3 (
Surgeon 919 (16) 565 (32) 2 (
EP or cardiac catheter lab implant setting 4212 (75) 1199 (68) 364 (
General anesthesia 372 (7) 7 (b1) 4 (
IPG = implantable pulse generator; EP = electrophysiology; IQR = interquartile range; SD =
a Other includes syncope, (bradycardia due to) atrial ﬁbrillation and supraventricular arrhyt
b Overweight deﬁned as BMI (kg/m2) between 25 and 29 and obese deﬁned as BMI N 30.
c Specialization of physician was self-reported.Table 3 reports the baseline and initial treatment characteristics of
patients who received ICD therapy stratiﬁed by region. The proportion
of males was higher in the ICD cohort compared to the IPG cohort
(82% vs 54%, p b 0.001) and ranged from 77% in South Africa and Latin
America to 89% in India. Primary prevention as an indication for implant
was highest in the Middle East (66%) and Western Europe (70%) and
lowest in South Africa (25%) (p b 0.001). In all regions there was a
small proportion of patients that had NYHA class II and QRS N 150 ms
or NYHA III/IV and QRS N 120 ms with LVEF b 35% (Table 3). The use
of a single chamber device was lowest in the Middle East (25%) and
highest in Western Europe (92%) (p b 0.001). The use of deﬁbrillationLatin America Middle East South Africa Western Europe
68 n (%) n = 840 n (%) n = 782 n (%) n = 827 n (%) n = 1006 n (%)
56,74) 74 (64,80) 65 (51,74) 72 (62,80) 76 (70,81)
64) 431 (51) 406 (52) 461 (56) 612 (61)
20) 266 (32) 187 (24) 512 (62) 461 (46)
77) 529 (62) 561 (72) 218 (26) 465 (46)
3) 54 (6) 34 (4) 95 (11) 77 (8)
4.4) 26 (4.4) 29 (6.9) 27 (5.8) 27 (4.5)
46%) 416 (50%) 522 (67%) 363 (44%) 410 (41%)
15) 299 (36) 172 (22) 160 (19) 394 (39)
45) 531 (63) 425 (54) 376 (46) 601 (60)
32) 166 (20) 292 (37) 109 (13) 194 (19)
36) 103 (12) 156 (20) 206 (25) 217 (22)
5) 42 (5) 44 (6) 54 (7) 83 (8)
8) 25 (3) 48 (6) 91 (11) 53 (5)
11.4) 59 (11.8) 54 (11.6) 59 (12.6) 61 (12.8)
7) 122 (15) 50 (6) 35 (4) 140 (14)
30) 147 (18) 45 (6) 54 (7) 150 (15)
14) 43 (5) 9 (1) 19 (2) 49 (5)
1) 4 (1) 3 (b1) 18 (2) 5 (1)
48) 523 (62) 674 (86) 700 (85) 650 (65)
9) 69 (8) 57 (7) 83 (10) 265 (26)
1) 75 (9) 73 (9) 133 (16) 115 (11)
46) 438 (52) 326 (42) 287 (35) 547 (54)
16) 210 (25) 233 (30) 252 (31) 121 (12)
99) 385 (46) 741 (95) 124 (15) 73 (7)
1) 237 (28) 9 (1) 702 (85) 800 (80)
1) 211 (25) 15 (2) 0 (0) 126 (13)
99) 617 (74) 763 (98) 812 (98) 457 (45)
1) 178 (21) 24 (3) 59 (7) 100 (10)
standard deviation.
hmia.
Table 3
Baseline demographics, device and implant characteristics for ICD cohort by region.
Characteristics Total Eastern Europe India Latin America Middle East South Africa Western Europe
n = 1407 n (%) n = 322 n (%) n = 94 n (%) n = 129 n (%) n = 400 n (%) n = 61 n (%) n = 401 n (%)
Median age, years (IQR) 61 (52,70) 60 (52,68) 56 (48,66) 64 (54,73) 58 (48,67) 58 (44,66) 67 (58,73)
Male 1149 (82) 261 (81) 84 (90) 99 (77) 330 (83) 47 (77) 328 (82)
Indication for ICD
Secondary preventiona 643 (46) 216 (67) 64 (68) 60 (47) 137 (34) 46 (75) 120 (30)
Primary prevention 764 (54) 106 (33) 30 (32) 69 (54) 263 (66) 15 (25) 281 (70)
Body mass index (kg/m2)
Mean (SD) 28 (5.6) 28 (5.2) 25 (4.0) 27 (5.0) 29 (6.3) 28 (6.0) 28 (5.2)
Overweight/obeseb 865 (61%) 196 (61%) 32 (34%) 79 (61%) 295 (74%) 30 (49%) 233 (58%)
Previous or current smoker 699 (50) 168 (52) 18 (19) 53 (41) 220 (55) 24 (39) 216 (54)
Hypertension 774 (55) 195 (61) 21 (22) 63 (49) 236 (59) 25 (41) 234 (58)
Diabetes 481 (34) 49 (15) 29 (31) 26 (20) 227 (57) 3 (5) 147 (37)
Coronary artery disease 944 (67) 208 (65) 57 (61) 72 (56) 284 (71) 34 (56) 289 (72)
Prior myocardial infarction 609 (43) 154 (48) 25 (27) 42 (33) 166 (42) 18 (30) 204 (51)
Coronary artery bypass grafting 273 (19) 54 (17) 23 (25) 14 (11) 64 (16) 12 (20) 106 (26)
Mean ejection fraction, % (SD) 34 (13.3) 40 (14.3) 34 (14.8) 34 (15.0) 31 (10.9) 43 (15.7) 31 (11.2)
NYHA
I 232 (17) 48 (15) 9 (10) 25 (20) 111 (28) 8 (13) 31 (8)
II 594 (42) 138 (43) 46 (49) 45 (35) 164 (41) 9 (15) 192 (48)
III 313 (22) 97 (30) 14 (15) 27 (21) 35 (9) 7 (12) 133 (33)
IV 27 (2) 3 (1) 1 (1) 3 (2) 2 (1) 4 (7) 14 (4)
No heart failure 236 (17) 35 (11) 24 (26) 29 (23) 88 (22) 33 (54) 27 (7)
QRS duration N 120 ms 285 (20) 93 (29) 17 (18) 31 (24) 66 (17) 12 (20) 66 (17)
CRT indicationc 95 (7) 33 (10) 5 (5) 8 (6) 13 (3) 4 (7) 32 (8)
Atrial ﬁbrillation
Paroxysmal 117 (8) 51 (16) 3 (3) 5 (4) 20 (5) 4 (7) 34 (9)
Persistent/permanent 162 (12) 49 (15) 2 (2) 5 (4) 16 (4) 1 (2) 89 (22)
CHADS2 score 2 or more 830 (59) 190 (59) 33 (35) 66 (51) 242 (61) 15 (25) 284 (71)
Single chamber device 804 (57) 179 (56) 73 (78) 40 (31) 98 (25) 44 (72) 370 (92)
Specialization of implanting physiciand
Electrophysiologist 761 (54) 129 (40) 94 (100) 67 (52) 376 (94) 40 (66) 55 (14)
Cardiologist 417 (30) 42 (13) 0 (0) 38 (30) 0 (0) 21 (34) 316 (79)
Surgeon 206 (15) 150 (47) 0 (0) 24 (19) 2 (1) 0 (0) 30 (8)
EP or cardiac catheter lab implant setting 975 (69) 154 (48) 94 (100) 97 (75) 395 (99) 61 (100) 174 (43)
Anesthesia
General anesthesia 224 (16) 38 (12) 0 (0) 60 (47) 4 (1) 32 (53) 90 (22)
Deﬁbrillation testing performed 806 (57) 193 (60) 67 (71) 97 (75) 139 (35) 54 (89) 256 (64)
ICD = implantable cardioverter deﬁbrillator; EP = electrophysiology; IQR = interquartile range; SD = standard deviation.
a Secondary prevention indication includes: cardiac arrest (presumably) due to VT or VF, spontaneous sustained VT or VF with structural heart disease (symptomatic and non-
symptomatic), unexplained syncope with structural heart disease, unexplained syncope with (depressed EF and) inducible VT/VF.
b Overweight deﬁned as BMI (kg/m2) between 25 and 29 and obese deﬁned as BMI N 30.
c CRT indication deﬁned as LVEF b 35% with NYHA class II and QRS N 150 ms or NYHA III/IV and QRS N 120 ms.
d Specialization of physician was self-reported.
93F. Al Kandari et al. / IJC Heart & Vessels 4 (2014) 90–96threshold testing (DFT) at implant varied between regions from 35% in
theMiddle East to 89% in South Africa. There was no difference in age or
gender when comparing patients who received deﬁbrillation testing to
thosewho did not receive deﬁbrillation testing. A decline in the propor-
tion of patients receiving deﬁbrillation testing over time (2005–2007
66% vs 2008–2009 62% vs 2010–2011 48%, p for trend = 0.001) was
seen.
The CRT cohort was of similar age with the ICD cohort and younger
than the IPG cohort (63 years vs 61 (ICD) and 72 (IPG)). Table 4 reports
the baseline and initial treatment characteristics of patients who
received CRT therapy stratiﬁed by region. Notable differences between
regions in subject demographics include male gender ranging from
55% in India to 83% in Eastern Europe, and median age ranging from
58 years in India to 73 years in Western Europe. Regional variation in
the use of CRT-D vs CRT-Pwas considerable with 85% of the CRT devices
implanted in the Middle East having deﬁbrillator functionality com-
pared to only 12% in South Africa. 20% of the CRT-D cohort was female
compared to 33% of the CRT-P cohort, p b 0.001. In those that had QRS
data available, less than half of the CRT recipients in South Africa, had
a QRS N 120 ms. 50% of the patients had the LV lead implanted in the
posterolateral location, but in a signiﬁcant percentage of patients in
Eastern Europe and Latin America, the LV lead was implanted in the
middle lateral vein location. The use of deﬁbrillation threshold testing
(DFT) for CRT-D device implants varied between regions from 7% in
South Africa to 30% in Latin America.4. Discussion
The PANORAMA database provides unprecedented observational
data collected from more than 8500 subjects being treated for cardiac
rhythmdisturbances fromdiverse geographies, facilitating comparisons
and examination of patient demographics, disease comorbidities, and
implant practices. Despite some difﬁculties associated with conducting
research outside of the usualwestern settings, the importance of includ-
ing such subjects should not be underestimated; majority of RCT data
for cardiac rhythm disturbances are based on North American (US)
patients. However, when looking to the worldwide implanted CRM
devices, the US population receives only about 20% of the total number
of pacemakers and 40% of the total implanted ICDs [17].
The subjects enrolled in PANORAMA showed important differences
across the regions. Subjects from India and theMiddle Eastwere distinct
from those in other regional groups in terms of the high prevalence of
diabetes and coronary artery disease. This conﬁrms previous publica-
tions, and likely reﬂects genetic and environmental differences and
dietary preferences [9,18,19]. Differences across the regions were most
pronounced when looking at the indications and type of device, for
example in India, Latin America and the Middle East, there was more
use of IPG therapy in AV block (a more stark presentation) than sinus
node disease and in South Africa very few ICDs were implanted for pri-
mary prevention. It is likely that these differences reﬂect the economic
situation and reimbursement and insurance structureswithin a country,
Table 4
Baseline demographics, device and implant characteristics for CRT cohort by region.
Characteristic Total Eastern Europe India Latin America Middle East South Africa Western Europe
n = 1455 n (%) n = 400 n (%) n = 108 n (%) n = 116 n (%) n = 276 n (%) n = 469 n (%) n = 86 n (%)
Median age, years (IQR) 63 (54,71) 59 (51,67) 58 (50,66) 63 (53,71) 64 (56,72) 64 (56,72) 73 (67,77)
Male 1052 (72) 332 (83) 59 (55) 85 (73) 199 (72) 317 (68) 60 (70)
Body mass index (kg/m2)
Mean (SD) 29 (6.0) 29 (5.1) 25 (4.1) 26 (5.0) 30 (6.6) 30 (6.6) 27 (4.7)
Overweight/obesea 886 (61%) 260 (65%) 44 (41%) 52 (45%) 206 (75%) 277 (59%) 47 (55%)
Previous or current smoker 568 (39) 206 (52) 17 (16) 38 (33) 131 (47) 141 (30) 35 (41)
Hypertension 785 (54) 232 (58) 26 (24) 59 (51) 183 (66) 241 (51) 44 (51)
Diabetes 433 (30) 70 (18) 43 (40) 24 (21) 172 (62) 97 (21) 27 (31)
Coronary artery disease 616 (42) 199 (50) 46 (43) 33 (28) 139 (50) 143 (31) 56 (65)
Prior myocardial infarction 316 (22) 159 (40) 10 (9) 23 (20) 58 (21) 35 (8) 31 (36)
Coronary artery bypass grafting 245 (17) 74 (19) 17 (16) 8 (7) 47 (17) 71 (15) 28 (33)
Mean ejection fraction, % (SD) 29 (12.2) 28 (7.8) 23 (9.0) 23 (7.8) 25 (9.4) 35 (16.6) 30 (7.2)
NYHA
I 89 (6) 2 (1) 5 (5) 5 (4) 39 (14) 35 (8) 3 (4)
II 246 (17) 42 (11) 9 (8) 23 (20) 69 (25) 90 (19) 13 (15)
III 689 (47) 273 (68) 71 (66) 55 (47) 141 (51) 107 (23) 42 (49)
IV 318 (22) 82 (21) 23 (21) 25 (22) 22 (8) 163 (35) 3 (4)
No heart failure 93 (6) 1 (b1) 0 (0) 8 (7) 5 (2) 74 (16) 5 (6)
QRS duration, ms
Not reported 271 (19) 56 (14) 62 (57) 37 (32) 18 (7) 59 (13) 39 (45)
b120 385 (27) 42 (11) 4 (4) 12 (10) 45 (16) 275 (59) 7 (8)
120 to 150 378 (26) 120 (30) 9 (8) 26 (22) 128 (46) 79 (17) 16 (19)
N150 421 (29) 182 (46) 33 (31) 41 (35) 85 (31) 56 (12) 24 (28)
Left bundle branch block 712 (49) 264 (66) 82 (76) 49 (42) 173 (63) 98 (21) 46 (54)
Right bundle branch block 81 (6) 18 (5) 9 (8) 8 (7) 29 (11) 15 (3) 2 (2)
Atrial ﬁbrillation
Paroxysmal 147 (10) 45 (11) 3 (3) 2 (2) 27 (10) 59 (13) 11 (13)
Persistent/permanent 223 (15) 94 (24) 3 (2) 12 (10) 22 (8) 79 (17) 13 (15)
CHADS2 score 2 or more 931 (64) 265 (66) 53 (49) 65 (56) 211 (76) 285 (61) 52 (61)
CRT deﬁbrillator 682 (50) 212 (53) 31 (29) 87 (75) 234 (85) 58 (12) 60 (70)
Specialization of implanting physicianb
Electrophysiologist 775 (53) 175 (44) 108 (100) 74 (64) 273 (99) 116 (25) 29 (34)
Cardiologist 439 (30) 10 (3) 0 (0) 22 (19) 0 (0) 352 (75) 55 (64)
Surgeon 238 (16) 215 (54) 0 (0) 20 (17) 0 (0) 1 (b1) 2 (2)
EP or cardiac catheter lab implant setting 1246 (86) 229 (57) 108 (100) 105 (91) 275 (100) 461 (98) 68 (79)
General anesthesia 154 (11) 15 (4) 0 (0) 45 (39) 5 (2) 78 (17) 11 (13)
LV lead location
Postero lateral 545 (50) 107 (36) 42 (46) 28 (33) 86 (48) 269 (69) 13 (24)
Middle lateral vein 218 (20) 90 (30) 7 (8) 25 (30) 19 (11) 69 (18) 8 (15)
Basal posterior vein 66 (6) 15 (5) 1 (1) 2 (2) 36 (20) 8 (2) 4 (7)
Middle anterior vein 66 (6) 29 (10) 5 (6) 9 (11) 2 (1) 19 (5) 2 (4)
Middle posterior vein 38 (4) 14 (5) 0 (0) 7 (8) 14 (8) 1 (b1) 2 (4)
Other 113 (11) 34 (11) 30 (33) 8 (10) 21 (12) 20 (6) 0 (0)
Deﬁbrillation testing performedc 215 (15) 93 (23) 10 (9) 35 (30) 36 (13) 31 (7) 10 (12)
CRT = cardiac resynchronization therapy; EP = electrophysiology; LV = left ventricular; IQR = interquartile range; SD = standard deviation.
a Overweight deﬁned as BMI (kg/m2) between 25 and 29 and obese deﬁned as BMI N 30.
b Specialization of physician was self-reported.
c Counts and percentages based on CRT-deﬁbrillator devices only. Percentages do not always add to 100, due to missing values.
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primarily AV block in the early regional pacing era to more sinus node
disease when cardiac pacing has become more common [20]. Of the
34 participating countries, 71% are considered to be emerging or devel-
oping economies, based on International Monetary Fund (IMF) guide-
lines [21]. This represents 82% of the study population.
The diagnosis of AF appeared to be comparatively low in Latin
America, India and the Middle East. Recent evidence is indicating that
even small amounts of AF regardless of symptoms may be correlated
with increased stroke risk [22].
Also seen were expected patterns such as the higher use of general
anesthesia which reﬂects local preferences. Other observations were
more difﬁcult to explain such as DFT at implants for ICD devices with
and without CRT capability. This may reﬂect changing attitudes about
the clinical need for DFT at implant, for which the evidence base is
growing [23–25].
In general, the PANORAMA IPG cohort overall was similar to previ-
ously reported cohorts. Compared to the DINAMIT and MADIT-II trials,the PANORAMA ICD cohort had slightly more comorbidities present at
implant [26,27] but when compared with previous secondary preven-
tion studies our cohort was similar [28]. We saw a higher prevalence
of single chamber ICD use, predominantly in Western Europe, India
and South Africa as compared to other regions. This may not only be
reﬂective of economic realities, but may also indicate differing attitudes
regarding the level of evidence available for patients without a pace-
maker indication [29]. The PANORAMA study included CRT patients
with a fairly typical patient proﬁle. When compared to the European
CRT survey [16] our cohort was of similar age but had more CRT-P
patients and slightly more patients with NYHA II. There were a num-
ber of patients receiving CRT therapy despite the lack of documentation
of a QRS duration greater than 120 ms. Although it might be possible
that the QRS duration has been less documented for those patients
with a QRS duration greater than 120 ms, it might also be that the
PANORAMA reﬂects real clinical practice of implanting CRT devices for
other (clinical) reasons, irrespective of the QRS duration. There is evi-
dence that CRT devices are electively implanted in patients with a QRS
95F. Al Kandari et al. / IJC Heart & Vessels 4 (2014) 90–96duration below 150ms after total AV node ablation for AF [30,31]. How-
ever, this cannot be conﬁrmed by the PANORAMA data since prior AV
nodal ablation information had not been collected.
Regardless of the reasons for heterogeneity in subjects and therapy
practice these differences are likely to impact the outcomes for patients.
A smoking history was present in more than 50% of the male ICD and
CRT patients, and from the male patients receiving a ﬁrst ICD up to
24% (Middle East) was smoking at the time of device implant. From
the male patients receiving a ﬁrst CRT the percentage of current
smokers was up to 18% (South Africa and Eastern Europe). As failure
to stop smoking will likely have a negative impact on survival of these
patients, especially those with ischemic heart disease, the PANORAMA
data may indicate a need to strongly emphasize smoking cessation
possibilities to patients before receiving a medical device.
5. Study limitations
These data need to be interpreted in the context of the limitations of
the study. This was a single-manufacturer sponsored study where spe-
ciﬁc device characteristics might limit applicability across all device
manufacturers; however, an attempt was made to compare general
therapy parameters that would apply regardless of the manufacturer.
In this global analysis, some regions of the world were not represented,
but this is the most regionally diverse dataset reported to date. The
number of centers and countries represented in the data may not be
sufﬁcient to accurately characterize the full regional practice and some
of the differences observed could be center speciﬁc. Some countries
limited the type of device enrolled, so broad conclusions about the
proportion of IPG/ICD/CRT use are not possible. To limit overinterpreta-
tion, in cases where the number of patients was limited (speciﬁc device
types), general observations were avoided in this report.
Missing data could have introduced biases and where substantial
data was missing it has been reported and interpreted with caution.
Some of the measures of patient conditions were collected without
speciﬁc deﬁnition (e.g. hypertension), potentially introducing vari-
ability into the response; however, these measures are interpreted
in a broad, non-quantitative manner. No adjustments were made for
multiple comparisons; however, results are reported with p values so
the reader can interpret the clinical and statistical signiﬁcance of the
results.
6. Conclusions
We provide comprehensive descriptive data on patients receiving
cardiac rhythm management devices from a range of geographies that
is not typically reported in literature; this may aid in the interpretation
and application of ﬁndings from other studies. We found signiﬁcant
variations in age, cardiovascular diseases, rhythm disturbances, type of
device implant, and implant practices across the regions. Some of these
may be reﬂections of larger socioeconomic variations, while others
may be due to regional guidelines and practice preferences.
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